

Oncology Today with Dr Neil Love: Management of Pancreatic Cancer
(Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following eligibility criteria was applied in the POLO trial evaluating maintenance olaparib for patients with metastatic pancreatic cancer who had not experienced disease progression on first-line platinum-based chemotherapy?
 - a. Eligible patients had germline BRCA mutations only
 - b. Eligible patients had either somatic or germline BRCA mutations
2. Which of the following outcomes was demonstrated in a recent randomized study by O'Reilly and colleagues evaluating cisplatin/gemcitabine alone or in combination with the PARP inhibitor veliparib as first-line therapy for patients with advanced pancreatic cancer and germline BRCA/PALB2 mutations?
 - a. A high response rate with cisplatin/gemcitabine alone
 - b. A significant improvement in response rate with the addition of the PARP inhibitor
3. Which of the following toxicities have been most frequently associated with olaparib?
 - a. Ocular and dermatologic toxicities
 - b. Neurologic and cardiovascular toxicities
 - c. Gastrointestinal toxicities and cytopenias
4. Which of the following efficacy outcomes was demonstrated in the SWOG-S1505 trial evaluating neoadjuvant modified FOLFIRINOX versus *nab* paclitaxel/gemcitabine for patients with resectable pancreatic cancer?
 - a. A significant improvement in overall survival with modified FOLFIRINOX
 - b. A significant improvement in overall survival with *nab* paclitaxel/gemcitabine
 - c. No significant difference in overall survival between the study arms